PRA Health Sciences (NASDAQ:PRAH) Downgraded by BidaskClub to Strong Sell

PRA Health Sciences (NASDAQ:PRAH) was downgraded by BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued on Wednesday, May 22nd, BidAskClub reports.

PRAH has been the topic of a number of other reports. ValuEngine raised shares of PRA Health Sciences from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. Mizuho set a $100.00 price target on shares of PRA Health Sciences and gave the company a “hold” rating in a research report on Friday, May 3rd. SunTrust Banks lifted their price target on shares of PRA Health Sciences to $120.00 and gave the company an “average” rating in a research report on Monday, March 4th. Wolfe Research started coverage on shares of PRA Health Sciences in a research report on Tuesday, April 2nd. They set a “market perform” rating for the company. Finally, Robert W. Baird lifted their price target on shares of PRA Health Sciences from $119.00 to $122.00 and gave the company an “outperform” rating in a research report on Thursday, February 28th. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $113.22.

Shares of NASDAQ PRAH traded down $0.49 during trading on Wednesday, hitting $95.93. The company had a trading volume of 372,911 shares, compared to its average volume of 538,496. PRA Health Sciences has a fifty-two week low of $82.12 and a fifty-two week high of $121.98. The firm has a market cap of $6.33 billion, a price-to-earnings ratio of 24.41, a price-to-earnings-growth ratio of 1.30 and a beta of 1.08. The company has a quick ratio of 0.90, a current ratio of 0.90 and a debt-to-equity ratio of 1.12.

PRA Health Sciences (NASDAQ:PRAH) last announced its earnings results on Wednesday, May 1st. The medical research company reported $1.10 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.95 by $0.15. PRA Health Sciences had a net margin of 5.50% and a return on equity of 26.87%. The business had revenue of $722.00 million for the quarter, compared to analyst estimates of $730.84 million. During the same quarter last year, the business earned $0.85 earnings per share. The company’s revenue for the quarter was up 2.9% compared to the same quarter last year. Equities research analysts anticipate that PRA Health Sciences will post 4.63 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Pendal Group Ltd purchased a new stake in shares of PRA Health Sciences during the 4th quarter worth approximately $70,530,000. Standard Life Aberdeen plc lifted its position in shares of PRA Health Sciences by 508.0% during the 4th quarter. Standard Life Aberdeen plc now owns 807,592 shares of the medical research company’s stock worth $72,365,000 after buying an additional 674,758 shares during the last quarter. Vanguard Group Inc lifted its position in shares of PRA Health Sciences by 12.8% during the 3rd quarter. Vanguard Group Inc now owns 5,811,972 shares of the medical research company’s stock worth $640,421,000 after buying an additional 658,191 shares during the last quarter. AQR Capital Management LLC lifted its position in shares of PRA Health Sciences by 48.7% during the 1st quarter. AQR Capital Management LLC now owns 1,825,143 shares of the medical research company’s stock worth $199,032,000 after buying an additional 597,699 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of PRA Health Sciences during the 4th quarter worth approximately $53,228,000. Institutional investors own 99.43% of the company’s stock.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

See Also: What type of investment options does a Roth IRA provide?

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.